TrialCompass TCL
Back to results
RecruitingPriority 4 · Lower priorityNCT06382844

Novel Flow-cytometry Approaches to Improve the Detection of Tumor Cells in CTCL

ClinicalTrials.gov

Plain-language summary

This trial is studying Detection and quantitation of (blood) tumor cells in patients with mycosis fungoides (MF) / Sézary syndrome (SS). for people with cutaneous T-cell lymphoma (skin lymphoma). The study measures how well this treatment works and monitors for side effects. This trial does not currently list US sites.

Who can join (key eligibility)

  • Age 18 Years or older
  • See full trial listing for complete eligibility

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

Detection and quantitation of (blood) tumor cells in patients with mycosis fungoides (MF) / Sézary syndrome (SS). (DIAGNOSTIC_TEST): Specific, sensitive, and reproducible (blood) detection and quantitation of tumor cells in patients with mycosis fungoides (MF) / Sézary syndrome (SS)

Drugs / treatments
Detection and quantitation of (blood) tumor cells in patients with mycosis fungoides (MF) / Sézary syndrome (SS).
Treatment length
Ask the trial team for details
Visit frequency
Ask the trial team for details
TrialCompass — Clinical Trial Summary

Novel Flow-cytometry Approaches to Improve the Detection of Tumor Cells in CTCL

NCT06382844

Phase: | Status: Recruiting | Priority: Lower

Plain-language summary

This trial is studying Detection and quantitation of (blood) tumor cells in patients with mycosis fungoides (MF) / Sézary syndrome (SS). for people with cutaneous T-cell lymphoma (skin lymphoma). The study measures how well this treatment works and monitors for side effects. This trial does not currently list US sites.

Who can join

  • Age 18 Years or older
  • See full trial listing for complete eligibility

What's being tested

Detection and quantitation of (blood) tumor cells in patients with mycosis fungoides (MF) / Sézary syndrome (SS). (DIAGNOSTIC_TEST): Specific, sensitive, and reproducible (blood) detection and quantitation of tumor cells in patients with mycosis fungoides (MF) / Sézary syndrome (SS)

Drugs / treatments: Detection and quantitation of (blood) tumor cells in patients with mycosis fungoides (MF) / Sézary syndrome (SS).

Treatment length: Ask the trial team for details

Visit frequency: Ask the trial team for details

Trial design

Non-randomized, blind

Enrollment target: 100 patients

Primary endpoint: Optimizing Marker Combination for Specific Identification and Quantification of Sézary Cells using Spectral Flow Cytometry

Ages: 18 Years to —

Start date: 2024-01-01 | Est. completion: 2026-12-31

Locations

0 US sites · 1 total

Contact

Julia M Almeida Parra, Prof. | jalmeida@usal.es | +34 923 29 45 00

Sponsor: Instituto de Investigación Biomédica de Salamanca (OTHER)

Tags

CTCL · any

View on ClinicalTrials.gov

https://clinicaltrials.gov/study/NCT06382844

Prepared using TrialCompass (trialcompass.com) on June 19, 2026. For informational purposes only. Always discuss with your healthcare team.